Just found it as well: http://www.finnewsnetwork.com.au/archives/finance_news_network77564.html Shares in QRxPharma Limited (ASX:QRX) have plunged more than 50 per cent on the news they will halt development of Moxduo. The pharmaceutical company announced in late May the pain drug had failed to receive approval from the US Food and Drug Administration. The company says the time and cost of further development would not be commercially justifiable. Shares in QRxPharma are trading down 50.68 per cent at $0.04